CASI Pharmaceuticals settles Evomela arbitration

CASI Pharmaceuticals has entered into a Settlement Agreement with Acrotech Biopharma to resolve an arbitration over the Evomela® license in China.

Rhea-AI Filing Summary

CASI Pharmaceuticals has entered into a Settlement Agreement with Acrotech Biopharma to resolve an arbitration over the Evomela® license in China. The dispute stemmed from Acrotech’s purported termination of a 2014 License Agreement covering exclusive commercialization rights in China.

Under the settlement, the prior purported termination and related agreements will be rescinded, and the License Agreement will remain in full force and effect, subject to certain revisions, including an obligation for CASI to purchase a minimum number of Evomela® units in specified years. CASI and Acrotech will now seek dismissal of the arbitration with prejudice, removing this legal overhang.

Positive

• Arbitration resolved with license reinstated: CASI and Acrotech agreed to rescind the prior purported termination of the Evomela® License Agreement, keeping CASI’s exclusive commercialization rights in China in force and seeking dismissal of the arbitration with prejudice, which reduces legal uncertainty around this asset.

Negative

• None.

Insights

Biopharma legal and licensing analyst

CASI restores its Evomela China license while eliminating arbitration risk.

The company has settled its arbitration with Acrotech over Evomela®, rescinding the prior purported termination of the 2014 License Agreement. This keeps CASI’s exclusive commercialization rights in China in place, albeit with revised terms.

A key revision is CASI’s commitment to purchase a minimum number of Evomela® units in certain years, which may increase future purchase obligations but also signals continued product access. Seeking dismissal of the arbitration with prejudice reduces legal uncertainty; future filings may clarify the financial impact of the new purchase commitments.

Key Figures

License Agreement date: September 17, 2014 Assignment to Acrotech: March 1, 2019 Form 6-K report month: June 2026

3 metrics

License Agreement date September 17, 2014 Date of original Evomela® License Agreement between Spectrum and CASI

Assignment to Acrotech March 1, 2019 Date License Agreement was assigned from Spectrum to Acrotech

Form 6-K report month June 2026 Month of the Form 6-K reporting the settlement

Key Terms

Settlement Agreement, arbitration proceeding, License Agreement, dismissal with prejudice, +1 more

5 terms

Settlement Agreement legal

"the Company entered into a Settlement Agreement (the “Settlement Agreement”) with Acrotech Biopharma Inc."

A settlement agreement is a legally binding deal where two sides resolve a dispute—often a lawsuit—by agreeing on terms such as payments, actions, or changes in behavior instead of continuing the case to trial. For investors it matters because settlements can create immediate costs, limit future liabilities or risks, and change a company's cash flow, reputation, or ongoing obligations much like paying a negotiated bill to avoid a lengthy, uncertain fight.

arbitration proceeding legal

"with respect to the settlement of the arbitration proceeding previously reported by the Company"

License Agreement legal

"termination of certain license agreement (the “License Agreement”), dated September 17, 2014"

A license agreement is a contract where the owner of intellectual property, technology, a brand, or other rights gives another party permission to use those assets under specified conditions, usually for fees, royalties or other payments. For investors it matters because such deals create or limit predictable revenue streams, affect profit margins, transfer legal and commercial risk, and can determine how quickly a company can grow — like renting out a patented tool to earn steady income while keeping ownership.

dismissal with prejudice legal

"the parties shall now seek dismissal with prejudice of the arbitration"

A dismissal with prejudice is a court ruling that ends a lawsuit permanently and prevents the same claim from being filed again. For investors, it matters because it removes ongoing legal uncertainty and potential future liability for the company, much like locking a file cabinet so a problem can’t be reopened; that clarity can affect a company’s risk profile, legal costs and valuation.

forward-looking statements regulatory

"This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

FAQ

What did CASI Pharmaceuticals (CASIF) announce in this Form 6-K?

CASI Pharmaceuticals announced a Settlement Agreement with Acrotech Biopharma resolving an arbitration over the Evomela® license in China, rescinding the prior purported termination and keeping the License Agreement in force with certain revisions.

How does the settlement affect CASI Pharmaceuticals’ Evomela rights in China?

The settlement rescinds the prior purported termination of the Evomela® License Agreement, so CASI’s exclusive rights to commercialize Evomela® in China remain in full force and effect, subject to agreed revisions between CASI and Acrotech Biopharma.

What happens to the arbitration between CASI Pharmaceuticals and Acrotech?

Following the Settlement Agreement, CASI Pharmaceuticals and Acrotech will seek dismissal of the arbitration with prejudice, meaning the arbitration proceeding is intended to be formally ended and cannot be refiled on the same claims.

What new obligations does CASI Pharmaceuticals have under the settlement?

Under the revised arrangements, CASI Pharmaceuticals is required to purchase a certain minimum number of units of Evomela® for specified years, creating defined purchase commitments tied to the continued Evomela® commercialization rights in China.

How is this Form 6-K used in CASI Pharmaceuticals’ registration statements?

The information in this Form 6-K is incorporated by reference into CASI’s Form F-3 registration statements (File Nos. 333-283998 and 333-281621), becoming part of those offerings’ disclosures unless later superseded by additional filings.

What risks does CASI Pharmaceuticals highlight around forward-looking statements here?

CASI notes that forward-looking statements involve inherent risks and uncertainties, and that various factors could cause actual results to differ materially. The company points investors to its SEC filings for further discussion of these risks and does not undertake ongoing updates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 06:30 AM Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE
13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For the month of June, 2026

Commission File Number  001-41666

CASI PHARMACEUTICALS, INC.

(Translation of registrant’s name into English)

1701-1702, China Central Office Tower 1

No. 81 Jianguo Road, Chaoyang District

Beijing, 100025

People’s Republic of China

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.  Form 20-F  x    Form 40-F  ¨

INCORPORATION BY REFERENCE

The information included in this Report on Form 6-K is hereby incorporated by reference into the Company's Registration Statements on Form F-3 (File No. 333-283998 and No. 333-281621) (including any prospectuses forming a part of such registration statement) and is to be a part thereof from the date on which this Report on Form 6-K is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

CASI Pharmaceuticals Announces Settlement of Arbitration

CASI Pharmaceuticals, Inc. (OCTQB: CASIF, the “Company”), a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases, today reported that the Company entered into a Settlement Agreement (the “Settlement Agreement”) with Acrotech Biopharma Inc. (“Acrotech”) with respect to the settlement of the arbitration proceeding previously reported by the Company in a current report on From 6-K on April 9, 2025. The arbitration proceeding was initiated in relation to Acrotech’s purported termination of certain license agreement (the “License Agreement”), dated September 17, 2014, between Spectrum Pharmaceuticals, Inc. and the Company granting the exclusive rights to the Company to commercialize Evomela^® in China, which was later assigned to Acrotech on March 1, 2019.

Pursuant to the Settlement Agreement, prior purported termination of the License Agreement and related agreements shall be rescinded and the agreements shall be in full force and effect, subject to certain revisions, including but not limited to the Company’s obligation to purchase a certain minimum number of units of Evomela^® for certain years. Pursuant to the Settlement Agreement, the parties shall now seek dismissal with prejudice of the arbitration.

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Among other things, the business outlook and quotations from management in this announcement, as well as the Company's strategic and operational plans, contain forward-looking statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement. Further information regarding these and other risks is included in the Company's filings with the SEC. All information provided herein is as of the date of this announcement, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law. We caution readers not to place undue reliance on any forward-looking statements contained herein.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CASI Pharmaceuticals, Inc.
	By:	/s/ Wei-Wu He
	Name:	Wei-Wu He
	Title:	Chairman to the Board
Date: June 29, 2026